



TARPSWG Semi-Annual Meeting,

Dublin, Wednesday Nov 1, 2023, 8am-12pm.

Wicklow Hall 2 – 2nd floor of the Convention Centre – Dublin

Attending: Markus Albertsmeier, Max Almond, Christina Angeles, Jyoti Bajpai, Giacomo Giulio Baldi, Elizabeth Baldini, Alexia Francesca Bertuzzi, Andrew Bishop, Sylvie Bonvalot, Savtaj Brar, Dario Callegaro, Ken Cardona, Jun Chen, Tom Wei-Wu Chen, Gennigens Christine, Sara Coppola, Andrea Covelli, Aimee M Crago, Vittoria D'Amato, Gina D'Amato, Lorenzo D'Ambrosio, Tom Delaney, Anant Desai, Nicolas Devaud, Palma Dileo, Fahima Dossa, Ashley Drohan, Chiara Fabbroni, Jeffrey Farma, Marco Fiore, Samuel Ford, Annamaria Frezza, Dorian Yarih Garcia Ortega, Maikim Gervais, Rebecca Gladly, Neha Goel, Valerie Grignol, Alessandro Gronchi, David Gyorki, Rick Haas, Andrew Hayes, Angela Hong, Paul Huang, Alexandra Istl, Boris Itkin, Shintaro Iwata, Jens Jakob, Daniel Jordão, John Kane, Bernd Kasper, Miranda Lam, Nicole Larrier, Katie Lee, Elizabeth Lilley, Lars Lindner, Andrea MacNeill, Joshua Mammen, Gary Mann, Rosalba Miceli, Roxanne Moore, Carolyn Nessim, Marko Novak, Emanuela Palmerini, Sandro Pasquali, Elisabetta Pennacchioli, Raphael Pollock, Joanna Przybyl, Sergio Damián Quildrian, Chandrajit Raut, Paul Ridgway, Christina Roland, Piotr Rutkowski, Kilian Salerno, Laura Samà, Roberta Sanfilippo, Catherine Sarre, Yvonne Schrage, Luke Selby, Joel Shapiro, Jeremy Sharib, Jason Sicklick, Myles Smith, Silvia Stacchiotti, Madeleine Strach, Dirk Strauss, Lorena P. Suarez Kelly, Carol Swallow, Joanna Szkandera, Ghazal Tansir, Anders Thornell, Fabio Tirota, Annalisa Trama, William Tseng, Dimitri Tzanis, Claudia Valverde, Winan Van Houdt, Nikolaos Vassos, Bruno Vincenzi, Rachel Voss, Micheal Wagner, Jiping Wang, Meng Welliver, Facundo Zaffaroni, Shane Zaidi, Felipe Bruscaglia, Costanza Figura, Alexander Lee, Gloria Marquina, Walter Nardi, Adam Fontebasso, Geoffrey Danieau, Michelle Wilkinson, Stjin van der Burg, Leah Winer, Bilal Marwa, Hadeel Halalshgh, Laura Madanat, Antonia Digkila, Priyanka Banga, Jessica Harewood, Surinder Kumar, Rosa Alvarez, David Konieczkowski, Ilaria De Benedictis, Marie Vinches

Online: Dagmar Adamkova Krakorova, Samuel Aguiar, Salvatore Asero, Yael Babichev, Yen-Lin Chen, David Coker, Moritz Kath, Edward Kim, Piotr Kobiela, Lenka Kristková, Herbert Loong, Eyal Mor, Shraddha Patkar, Daniela Salvatore, Jacek Skoczylas, Eva Wardelmann, Andrea Vanzulli, Sohayb Faleh, Franziska Neeman, Tomas Soule

Apologize: Ferdinando Cananzi, Charles Catton, Chiara Colombo, Attila Kollar, Aiko Maejima, John Mullinax

1. Welcome & Introduction of new members – P. Ridgway/M. Smith/A. Gronchi

2. STRASS2/STREXIT2 Update – W. vanHoudt

- 77pts of Nov 1 2023; accrual behind but picking up (INT Milan with 23pts, top recruiting site)
- Europe, Canada centers open
- US centers open to recruitment: 28 total sites as of Oct 2023 (19 activated and 9 pending)
- Japan centers will open soon
- STREXIT2 amendment submitted. Provisional start date Q2 2024. Centers participating to STREXIT2 will need to enrol >1 patients in STRASS2.
- There are monthly meetings to discuss eligibility and to increase accrual and managing challenging clinical settings.

3. Education Committee/Webinar Series update – D. Callegaro/J Farma

- Transition to a Journal club series
- Will be alternating with with RPS tumor board (rejected the idea of combining on same day)
- New Zoom platform from TARPSWG thanks to Italian patient's donation

4. International Tumour Board update/paper – J. Sicklick

- Published a report on the first 24 tumour boards in Annals of Surgical Oncology
- 74 cases discussed, 36 different institutions and different countries

- Attendance decreasing over time (specifically over the past 4 months has been waning)
- Ideal time to be re-consider to include Asia/Oceania time zones

5. **RESAR update** – M. Fiore

- **Update on Contracts and IT for Centralization** – M. Fiore
- 46 centers recruiting, 16 approved, 3 more centers are in submission to IRB and 23 declaration of interest
- Be sure IRB is updated (refer to daniela.salvatore@resarplatform.com)
- Ongoing progress on RESAR “going live”. The RESAR platform website is online since September 25th at www.resarplatform.com
- ~700 pts have been centralized to platform from 6 centers (out of approx. 3500)
- For 5 studies, many centers are late in signing Framework Agreement and/or centralizing data to Milan. Please local PIs contact marco.fiore@resarplatform.com
- New Framework Agreement: All RESAR centers must be part of it and is open to any new center, we can run trials through it and also for Retrospective studies like PelviSarc which has great potential (provided the centralization of data to Milan)

- **RESAR governance** – D. Gyorki

- RESAR is 7 years old – time to start larger studies and re-think structure of the collaborative.
- It has been established a structure that will include a Governance Chair, Governance Committee and Executive Committee (see full document attached for details)
- The Governance Committee will include permanent members from the top 10 recruiting sites, and non-permanent members to guarantee inclusion from whole TARPSWG membership
- Executive Committee will be a small operational group
- **ACTION ITEM:** A call for volunteering in Governance Committee and Executive Committee is open, any TARPSWG member interested in being a member please submit a letter of interest and your CV BEFORE NOVEMBER 17th to David Gyorki: David.gyorki@petermac.org
- RESAR Investigator’s Meeting will be held online in January 2024

- **SARveillance update** – S. Ford, D. Maes

- Will be first prospective randomized trial within RESAR registry
- Primary outcome is Quality of Life
- Secondary Outcome is OS
- Ready to Launch
- Two ways to open the trial of :
- Preferred way is through RESAR – be part of the data sharing framework and have SARVEILLANCE specific REB and sign the DUF for the center
- Opportunity to participate outside of RESAR via individual institutional prospective database which would require DTA agreement with Birmingham group, and will be included in pre-planned Metanalysis
- Study design reviewed: QoL component will be through separate platform
- Specific data points for SARveillance already incorporated in RESAR Platform, included the randomization tool
- Retrospective SARveillane data/results discussed

- Did a survey to TARPSWG – 58 centers responded – paper was published – heterogeneity in surveillance strategies
- **Retrospective SARveillance** – looking at surveillance on oncologic outcomes and management of recurrence, main road block is the DSA but finally solved.

6. Clinical Trial Committee – C. Roland

- **ReLapse** – Angela Hong
 - Prospective Observational Study on Pre-op Radiation for recurrent RPS – two arms with and without radiation
 - Protocol finalized. Email to come in the upcoming weeks to those want to participate
 - Aim is 100 patients over 3 years
 - Primary endpoint: Abdominal-pelvic recurrence free survival
 - Secondary endpoints: OS, Distant disease, toxicity, pathologic and radiologic response, Quality of Life
 - 45-50Gy and centralized QA committee – cloud based platform to upload the plan for centralized review before enrolling
 - RedCap database for entry
 - IRB approval in Australia obtained
 - Trying to get ReLapse within the RESAR Framework Agreement system, but adjustments are need to be discussed, since ANZSA is sponsor of the study
 - Comments from the audience:
 - 45Gy is too low – should be 50Gy for everyone
 - Remove after radiation Quality of Life and keep 2 weeks post surgery which would capture both
- **Hypofract RP** – M. Lam, C. Raut
 - What is the safety of using Hypofractionated Radiation
 - Phase I: approved at Dana Farber as a preliminary study
 - 2.85Gy x 15 over 3 weeks – is it safe with regards to surgical complications and toxicity. There is a de-escalation arm.
 - Phase II: Is pre-op Hypofractionated in Primary and Recurrent LPS Safe?
 - Primary outcome: 30-day complication rate
 - Many secondary outcomes and translational projects within it
 - Discussion that study should be on primary tumors only and recurrent should be excluded

7. Translational Research Committee – R. Gladdy

- **Proteomics** – P. Huang
 - Fantastic presentation on the role of proteomics as a biomarker for risk stratification—prelim work in RPS ongoing.
- **Molecular subtyping/profiling for LMS** – A. Fontebasso, R. Gladdy
 - Molecular subtyping of LMS to make it a reality
 - How can we work together to move this project forward?
 - Need biobanking

- International collaboration helps to advance things
- Integrating high throughput technologies will have them validated in the clinical setting and having it work on FFP specimens
- Achieve Molecular prognosis is the goal
- **GIST – J. Sicklick**
 - Another great translational talk on our understanding (or new understanding) of cell of origin of GIST using bulk transcriptomics
- **ctDNA -for STRASS2 – E. Keung, J. Mullinax**
 - Dr. Mullinax unfortunately delayed in transit, presentation postponed for next meeting

8. REC Committee update – C. Swallow

- **REC (Research Committee) Update – C. Nessim**
 - Majority of studies are on track and moving forward
 - Non-RESAR registry available to all PIs involved, the published papers, those in progress, new studies on shared registry online
- **Introduction of new Co-Chair**
 - Mai-Kim Gervais from the University of Montreal will be Co-Chair of REC from now on
 - Carolyn Nessim will be Chair for one more year and then Mai-Kim Gervais will become the Chair and there will be a callout for a Co-Chair
 - Can now use the Framework agreement for Data Sharing with RESAR for REC projects which will likely improve the bottleneck of REC studies.
- **iSARC – J. Farma**
 - 20 sites to date have signed DTA
 - Goal is complete data accrual by end of calendar year
 - Will get access to RedCap to enter patients.
 - Can still join if want, please contact Jeffrey Farma
- **RP Lipoma – W. Tseng**
 - Retrospective study on primary RP MDM2 non-amplified lipomatous tumors
 - Eligibility 2010-2020
 - 9 centers have expressed interest
 - Primary objective: frequency and disease history
 - Secondary objective: Presentation, Management and compare the outcomes of resection of Lipoma vs. WDLPS, disease specific mortality and OS, local recurrence
 - Min number is 1 case but no central path review
 - Deadline February 2024 to send data.
 - Goal would be for abstract submission for CTOS 2024
- **RPS Ewing's sarcoma- A. Borghi/D. Callegaro**
 - Retrospective study on intrabdominal Ewing's sarcoma (2002-2021)
 - Molecular analysis required
 - Centralized database on RedCap Platform
 - Inclusion: Any age (pediatric and adults) extra-skeletal Ewing's, non-metastatic and kidney, pancreas is included, primary and recurrent

- Exclusion: desmoplastic small round cell sarcomas, uterine
- Will follow WHO classification.
- Need molecular pathology to confirm diagnosis – if no molecular analysis, then excluded
- Outcomes: OS, DFS, Local Recurrence, post op complications

9. TARPSWG Governance and Transitions – C. Swallow

- Comments on Governance and the fact that we have less structure but are extremely effective and it is based on volunteerism.
- We should maintain it this way for now.
- If you are interested in being included in Committees, please reach out and express your interest

10. Closing remarks – A. Gronchi

- This is the 10-year anniversary of TARPSWG with the founding 8 centers, we have to congratulate ourselves!
- Harmonize surgical resection was the original idea and we have done so much more since then – creating a great community

**Next Semiannual Meeting will be held in occasion of SSO 2024 in Atlanta
on March 20th – Save the Date**